Louis Navellier likely had a good year last year, since the kinds of stocks he typically likes did very well (generally growth stocks, those with rapid earnings growth that beat estimates and grow at increasing rates … and often look expensive, with high PEs) — and he’s out now with a new ad about biotech stocks that he thinks will get you triple-digit gains.
Biotech teasers are on the rise these days, since we’ve been in a blistering biotech bull market for a couple years now — over the last year even the biotech index funds are up by 60-80% or so, and there have been dozens of huge winners that are up several hundred percent … mostly smaller stocks, of course, but even the biggies have done very well (Gilead (GILD) and Biogen-Idec (BIIB) come to mind, both are very large companies at or near $100 billion in market capitalization, and both have doubled over the last twelve months).
Just chasing growth in that sector would have put you in good stead over the last year, even if you had no skill or luck in choosing the best specific stocks — and an aging population in the highest-health-spending country helps to buttress future hopes for growth.
So we’ve now got pretty much an ideal backdrop for pitching biotech stocks, which — like mining stocks — have big individual boom and bust moves that attract speculators and traders, and lend themselves to good storytelling (curing disease, ending misery, huge secret discoveries by “lone wolf” scientists or prospectors, shocking gains, etc. etc.). I expect we’ll continue to see lots of overheated promises about the next hot biotech stock — and while I’ll often not be able to tell you much about the science or the real prospects, I can at least ID some stocks for you.
So what, then is Louis Navellier telling his subscribers to buy? He’s flogging his Emerging Growth newsletter in this particular pitch, and that’s about $1,000 a year, so I’m assuming you don’t much feel like subscribing just to find the stocks, right? Don’t worry, that’s why we’re here — his spiel touts three specific stocks that he’s recommending, let’s look for the first one now, the one he calls the “Next Biotech Doubler”:
“The Next Biotech Doubler…
“It’s NOT in the U.S. … or Europe … or even Japan…
“It’s in China, and it has the catbird seat for the next Avian Flu epidemic….”
Interestingly, some “plays on the bird flu outbreak” were also among the top performers on the Gumshoe tracking spreadsheets in 2013 — so is Navellier touting one of those stocks? We’ll find out shortly (That tout was from Tony Sagami, FYI, you can see it here — the top performer in that list was one he mentioned for free, not a teaser, and was BioCryst Pharmaceuticals (BCRX) with a gain of more than 500%).
Here’s what gives Navellier’s pitch some urgency, the possibility of global pandemic flu mutating from Avian Influenza:
“Avian Influenza. Bird Flu. H5N1.
“It’s a virus that boasts a mortality rate above 60%. In China, it kills two out of three infected.
“And for the first time ever, the highly-virulent H5N1 has crossed into the Americas.
“One week ago, the first human infection of H5N1 was reported in Canada. But it won’t be the last.
“I don’t want to scare you, because we’re not at pandemic levels—yet. H5N1 still can’t easily spread from person-to-person. And until that happens, we’re mostly safe here in the U.S.
“But in the meantime, this virus is endemic in China. Tens of millions of birds have been slaughtered and disposed of to limit the spread of bird flu, but human cases there continue to surge because of the virus’ fast-mutation ability.”
And, of course, “one company” holds the key to solving the problem.
Isn’t it always thus?
“… there is just one company that has the technology and the know-how, not to mention the full support of the Chinese government to fight this potential epidemic.
“Buy Shares Today, Enjoy Double-Digit Gains In Six Months…
“…And Triple-Digit Profits in a Year
“Already, this stock is up 10% since the latest H5N1 case in Canada was released, and this is just the beginning of an explosive move higher for these shares.
“This company—I’ll call it our #1 Biotech Winner of 2014— is one of the most innovative Chinese small-cap stocks that I’ve ever found.
“It dominates its niche because it is consistently able to adapt and create vaccines for the latest infectious disease trends far faster than its giant pharmaceutical competitors….
“… the Chinese government chose this company’s vaccine over the lumbering pharma giants as the only licensed H5N1 vaccine for China’s strategic stockpile.”
Navellier even takes a moment to pile on the lone Wall Street analyst who’s trying to predict this company’s earnings:
“… there is just a single analyst following the company, and if you’ll forgive me for a moment, he’s had a history of being dead wrong.
“Last quarter, this analyst expected the company to report a loss. Instead, the company reported a modest gain—surprising some 300% to the upside. And handing us hefty gains in the process.
“The quarter before that, wrong again. To the tune of a 133% earnings surprise.
“Before that, a 60% earnings surprise.
“So rather than getting better, this poor overworked analyst is actually getting worse!”
Navellier’s system relies in part on analyst surprises, and consistent “beats” of analyst estimates, so I guess it’s no surprise that this came to his attention — though one should never rely much on estimates when they come from just a single analyst, the value of analyst estimates and forecasts usually comes from the aggregate information and from the range of guesses (and a company’s ability to do better than average estimates).
A few more tidbits for the Thinkolator:
“… this analyst is STILL expecting the company to report a loss in the next quarter. And I have to say, I think we’re on the verge of an even bigger earnings upset.
“That’s because the company is no one-hit wonder. It stands to benefit—and massively so—as H5N1 continues to rear its deadly head, or if we see another outbreak of H1N1, but it also has a number of other profitable vaccines for diseases like hepatitis A, hepatitis B, influenza and SARS.
“And its latest vaccine is set to fight the Chinese epidemic of EV71, or Hand Foot and Mouth Disease, as cases continue to accelerate—from just over one million in 2010 to more than two million in 2012. There is no other treatment for EV71, and the company just completed its phase III clinical trials with strong results.
“What about its pipeline? Vaccines for pneumococcal, rotavirus, rabies, varicella, and rubella.”
So who is it? Well, we feed all of that into the hungry, gaping maw of the Mighty, Mighty Thinkolator and learn that this is almost certainly … Sinovac Biotech (SVA), which was one of the other solutions to one of the stocks teased by Tony Sagami last year and has done well since (up 75% or so). This is a China-focused vaccine company, their main products are vaccines for Hepatitis A and B and seasonal flu, and they also have a lump business in bird flu and swine flu vaccines (the customer is the government for those, so sales depend on whether or not the government is stockpiling during that quarter). Lately, the revenue driver has been their seasonal flu vaccine, Anflu, which generated about 40% of revenue last quarter (the two Hepatitis vaccines together were 48% of their core sales for the quarter — the rest was mostly the Panflu H5N1 vaccine for government stockpile, which they tally separately from the “normal” revenue.)
And yes, the lone analyst who provides an earning estimate for the current quarter has not exactly been on target — though I don’t know whether the company provides any real guidance or not, and I can’t imagine how hard it might be to guess at vaccine demand in Chinese cities, or to guess what portion of the business will be given to Sinovac. That analyst estimates another loss next quarter, and a second analyst piles on to provide an average estimate of a larger loss next year as revenue climbs from $70 million to $80 million and the company is expected to lose five cents a share. The average analyst price target is between $6.50-7, about where the stock is right now.
It’s a pretty good business, it appears, with several high-volume vaccines approved and another pending approval for a probably smaller market (The EV71 vaccine) — and it has very good gross margins, so it should be able to become profitable. My quick glance gives me the feeling that any potential spike in price would probably depend on more chatter about pandemic flu, or on sales ramping up more than has been the norm lately, but the basic underlying business in Hepatitis and flu vaccines is growing and should be enough to create sustainable profitability if they keep the rest of their costs down … maybe not growing enough to justify this valuation, but it looks like a viable business from this distance. I’d prefer to buy Chinese companies on the cheap if at all, particularly if I don’t really know anything about their management or how the marketplace works for their products, as is the case here, so I’m not super excited about the shares … but these kinds of vaccines should create a solid business in a large and densely populated country where vaccinations against infectious disease should be expected to be hugely important over time.
So there’s one idea for you, it looks like Navellier’s second pick is Ligand (LGND), a pharma royalty stock that I’ve covered a lot for the Irregulars and own personally, so I’ll get to that one in more detail and try to find the mysterious third pick for you tomorrow. Enjoy!